Amsterdam: CEO of the Saudi Food and Drug Authority (SFDA) Dr. Hisham Aljadhey affirmed that the Kingdom of Saudi Arabia, represented by the SFDA, is effectively integrating artificial intelligence technologies into drug regulatory work, thereby enhancing drug safety and quality. This effort aligns with Saudi Vision 2030, which focuses on innovation and modern technologies to achieve the greatest impact in the drug regulatory field.
According to Saudi Press Agency, Dr. Aljadhey made this statement at the International Coalition of Medicines Regulatory Authorities (ICMRA) Summit 2025, which was held at the European Medicines Agency (EMA) headquarters in Amsterdam, the capital of the Netherlands.
During the Summit, Dr. Aljadhey co-chaired a summit session titled "Artificial Intelligence in Regulatory Practices: Looking into the Future," alongside Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA) Lawrence Tallon.
The session discussed regulatory principles governing the use of AI technologies, reviewed the challenges of leveraging AI, and explored its role in shaping regulatory practices with global impact. It also included exchanging experiences and reviewing analytically-based decision-making mechanisms as outputs for regulatory authorities around the world.
The ICMRA Summit agenda, which was held from October 21 to 23, included meetings, discussions, and dialogue sessions focused on enhancing cooperation, capacity building, and the exchange of expertise and data among alliance members.
ICMRA is an international coalition of drug regulatory authorities that aims to enhance international cooperation among regulatory bodies, address challenges in drug safety, and develop related regulations and legislative frameworks.